LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Home・Lista de Ações・AbCellera Biologics Inc

AbCellera Biologics Inc

Fechado

SetorSaúde

3.51

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.44

Máximo

3.58

Indicadores-chave
By Trading Economics
Rendimento	48M -8.9M
Vendas	36M 45M
Margem de lucro	-19.942
Funcionários	562
EBITDA	22M -18M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+97.18% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	172M 1.1B
Abertura anterior	3.51
Fecho anterior	3.51

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

1.99 / 2.635 Suporte e Resistência

AbCellera Biologics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de mar. de 2026, 22:51 UTC

Ganhos

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 de mar. de 2026, 21:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 de mar. de 2026, 20:31 UTC

Ganhos

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 de mar. de 2026, 23:49 UTC

Conversa de Mercado

Notícias Principais

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 de mar. de 2026, 23:31 UTC

Conversa de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

18 de mar. de 2026, 22:49 UTC

Conversa de Mercado

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 de mar. de 2026, 22:41 UTC

Conversa de Mercado

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 de mar. de 2026, 22:36 UTC

Ganhos

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 de mar. de 2026, 22:24 UTC

Ganhos

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 de mar. de 2026, 22:23 UTC

Ganhos

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 de mar. de 2026, 22:23 UTC

Ganhos

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 de mar. de 2026, 21:58 UTC

Ganhos

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 de mar. de 2026, 21:55 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

18 de mar. de 2026, 21:55 UTC

Conversa de Mercado

Ganhos

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 de mar. de 2026, 21:40 UTC

Conversa de Mercado

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 de mar. de 2026, 21:16 UTC

Conversa de Mercado

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 de mar. de 2026, 21:00 UTC

Notícias Principais

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 de mar. de 2026, 20:58 UTC

Ganhos

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 de mar. de 2026, 20:41 UTC

Ganhos

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 de mar. de 2026, 20:29 UTC

Ganhos

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 de mar. de 2026, 20:25 UTC

Ganhos

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 de mar. de 2026, 20:17 UTC

Ganhos

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 de mar. de 2026, 20:14 UTC

Conversa de Mercado

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 de mar. de 2026, 20:09 UTC

Ganhos

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 de mar. de 2026, 20:07 UTC

Ganhos

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 de mar. de 2026, 20:06 UTC

Ganhos

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 de mar. de 2026, 20:04 UTC

Ganhos

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 de mar. de 2026, 20:04 UTC

Ganhos

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 de mar. de 2026, 20:04 UTC

Ganhos

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 de mar. de 2026, 20:03 UTC

Ganhos

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparação entre Pares

Variação de preço

AbCellera Biologics Inc Previsão

Preço-alvo

By TipRanks

97.18% parte superior

Previsão para 12 meses

Média 7 USD 97.18%

Máximo 7 USD

Mínimo 7 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para AbCellera Biologics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para AbCellera Biologics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.99 / 2.635Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.